Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
HSBC Cuts 10% of U.S. Debt Capital Markets Team Amid Ongoing Business Revamp 
Nvidia Nears $30 Billion Investment in OpenAI, Replacing Previous $100 Billion AI Partnership 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Freedom Finance and Binance Join Forces in Digital Assets 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Texas Attorney General Ken Paxton Sues Sanofi Over Alleged Healthcare Bribery Scheme 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
Meta Platforms Cuts Equity Awards Again Amid Massive AI Investment Push 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
 Patients for FLT3 Mutations - EconoTimes)
SAN DIEGO, May 08, 2018 -- Invivoscribe Technologies, Inc. announced today that they have submitted to Japan’s Pharmaceutical and Medical Devices Agency (PMDA) and the US Food and Drug Administration (FDA) product registrations based on the ongoing Phase III CL-0301 ADMIRAL study evaluating gilteritinib for the treatment of FLT3 mutation-positive (FLT3mut+) relapsed or refractory acute myeloid leukemia (AML) in adult patients.
Invivoscribe Technologies Inc., in collaboration with Astellas Pharma Inc., has developed a companion diagnostic to aid in identifying these FLT3mut+ AML patients. In Japan, Invivoscribe submitted a pre-market approval application (Shonin) with the PMDA for the LeukoStrat® CDx FLT3 Mutation Assay and in the United States, Invivoscribe submitted a Panel Track Supplement to update the FDA-approved LeukoStrat CDx FLT3 Mutation Assay’s Intended Use, specific for gilteritinib, should it be approved.
The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based in vitro diagnostic test designed to detect internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with AML. Invivoscribe was the first company to receive FDA approval for an AML companion diagnostic, with the approval of the LeukoStrat CDx FLT3 Mutation Assay in April of 2017.
“These submissions in Japan and the US represent a significant step in our ongoing efforts to harmonize molecular diagnostic testing for what is one of the most important driver mutations in AML in support of precision medicine,” said Jeffrey Miller, CSO & CEO of Invivoscribe.
According to the American Cancer Society, each year around 20,000 new cases of AML are diagnosed in the US alone, with one-third of these being FLT3mut+.
Invivoscribe Technologies Inc. is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the fields of personalized molecular diagnostics and personalized molecular medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies developing and commercializing companion diagnostics.
For additional information please visit www.invivoscribe.com.
CONTACT:
Kevin Dobyns 858-224-6600
